BLA 021684 · Emd Serono
Gonal-F Rff Redi-Ject
Follitropin Alfa/Beta · Subcutaneous · Gonadotropin
Last checked: Nov 20, 2026Latest source record: May 13, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
May 25, 2004
Approved uses
1
Original approval plus efficacy supplements
Registered trials
62
13 Phase 3, 3 recruiting
FAERS reports
54
46 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 3, 2025.
GONAL-f ® RFF Redi-ject ® is a prefilled gonadotropin-containing auto-injection device indicated for: Induction of ovulation and pregnancy in oligo-anovulatory women in whom the cause of infertility is functional and not due to primary ovarian failure ( 1.1 ) Development of multiple follicles in ovulatory women as part of an Assisted Reproductive Technology (ART) cycle ( 1.2 ) 1.1 Induction of Ovulation and Pregnancy in Oligo-Anovulatory Women in whom the Cause of Infertility is Functional and Not Due to Primary Ovarian Failure. Prior to initiation of treatment with GONAL-f ® RFF Redi-ject ® : Perform a complete gynecologic and endocrinologic evaluation Exclude primary ovarian failure Exclude the possibility of pregnancy Demonstrate tubal patency Evaluate the fertility status of the male partner 1.2 Development of Multiple Follicles in Ovulatory Women as Part of an Assisted Reproductive Technology (ART) Cycle. Prior to initiation of treatment with GONAL-f ® RFF Redi-ject ® : Perform a complete gynecologic and endocrinologic evaluation, and diagnose the cause of infertility Exclude the possibility of pregnancy Evaluate the fertility status of the male partner
Mechanism: Follicle stimulating hormone (FSH), the active component in GONAL-f ® RFF Redi-ject ® , is required for normal follicular growth, follicular maturation, and gonadal steroid production. The level of FSH is critical for the onset and duration of follicular development, and consequently for the timing and number of follicles reaching maturity. GONAL-f ® RFF Redi-ject ® stimulates ovarian follicular growth in women who do not have primary ovarian failure. In order to effect the final phase of follicle maturation, resumption of meiosis, and rupture of the follicle in the absence of an endogenous...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
4 products under this application
- GONAL-F RFF REDI-JECT · FOLLITROPIN ALFA/BETA 900 IU/1.5ML · INJECTABLE, SUBCUTANEOUS · Prescription
- GONAL-F RFF REDI-JECT · FOLLITROPIN ALFA/BETA 300 IU/0.5ML · INJECTABLE, SUBCUTANEOUS · Prescription
- GONAL-F RFF REDI-JECT · FOLLITROPIN ALFA/BETA 150 IU/0.25ML · INJECTABLE, SUBCUTANEOUS · Prescription
- GONAL-F RFF REDI-JECT · FOLLITROPIN ALFA/BETA 450 IU/0.75ML · INJECTABLE, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Follitropin Alfa/Beta" as an intervention, any sponsor and status, largest first.
- A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00696800 · 1,509 participants · Start Jun 27, 2006 · Primary completion Nov 19, 2007
Drug: Corifollitropin alfa; RecFSH / Follitropin beta (Days 1 to 7) and 6 more · For: In Vitro Fertilization
- Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01144416 · 1,424 participants · Start Jun 2010 · Primary completion Jul 2011
Drug: SCH 900962 / Corifollitropin alfa / Org 36286; RecFSH / follitropin beta and 2 more · For: Infertility
Lund UniversityAcademic, hospital or other
NCT03737253 · 810 participants · Start Sep 2016 · Primary completion Dec 31, 2021
Drug: Follitropin alpha; Menotropin · For: Female Infertility
Sites: Poznan, Poland; Malmö, Sweden
- MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo TransferPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT00884221 · 749 participants · Start Jul 2009 · Primary completion Jul 2010
Drug: Highly purified menotrophin; Recombinant FSH · For: Infertility
Sites: Anderlecht, Belgium; Brussels, Belgium; Edegem, Belgium · 25 sites in all
- Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist TreatmentPivotal-lookingRecruiting
Nanjing UniversityAcademic, hospital or other
NCT07128394 · 590 participants (planned) · Start Feb 1, 2024 · Primary completion Sep 30, 2026
Drug: Recombinant Luteinizing Hormone (rLH); Recombinant Follicle-Stimulating Hormone (rFSH) and 1 more · For: Infertility, Female; Luteinizing Hormone (LH)
Sites: Nanjing, China
- Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response PatientPivotal-lookingCompleted
Reproductive & Genetic Hospital of CITIC-XiangyaAcademic, hospital or other
NCT03300518 · 552 participants · Start Nov 15, 2017 · Primary completion Jun 18, 2021
Drug: Follitropin Beta;MSD; Ganirelix and 2 more · For: Infertility
Sites: Changsha, China
- Nordic Luveris StudyPivotal-lookingCompleted
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
NCT00553293 · 526 participants · Start Aug 2003
Drug: recombinant luteinizing hormone (Luveris); recombinant follicle stimulating hormone (Gonal-f) · For: Infertility; In Vitro Fertilization
Sites: Copenhagen, Denmark
- Efficacy of Corifollitropin Alfa Versus Follitropin Beta in Aged IVF (In-vitro Fertilization) PatientsPivotal-lookingCompleted
Vietnam National UniversityAcademic, hospital or other
NCT02466204 · 400 participants · Start Jun 1, 2015 · Primary completion Aug 10, 2016
Drug: corifollitropin alfa; Follitropin Beta · For: Infertility
Sites: Ho Chi Minh City, Vietnam · 2 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- ovarian hyperstimulation syndrome21
- off label use7
- foetal exposure during pregnancy6
- maternal exposure during pregnancy5
- abdominal distension4
- arnold-chiari malformation4
- drug interaction4
- exposure during pregnancy4
- hyperthyroidism4
- spina bifida4
- dyspnoea3
- optic nerve sheath meningioma3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 9 |
| 2021 | 2 |
| 2022 | 7 |
| 2023 | 9 |
| 2024 | 9 |
| 2025 | 6 |
| 2026 | 6 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of follitropin delta for ovarian stimulation in vitro fertilization/ intracytoplasmic sperm injection cycles: a systematic review with meta-analysis.
Palomba S, Caserta D, Levi-Setti PE, et al. · J Ovarian Res 2024 · Meta-Analysis, Systematic Review
Sponsor: Emd Serono
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.